Last reviewed · How we verify
oxygen inhalation
Oxygen inhalation, marketed by the University of Zurich, holds a unique position in the respiratory therapy market. The key composition patent is set to expire in 2028, providing a period of exclusive market protection. The primary risk lies in the lack of significant revenue data and clear primary indication, which may limit its commercial appeal and competitive edge.
At a glance
| Generic name | oxygen inhalation |
|---|---|
| Sponsor | University of Zurich |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Caracterization of the Combined Alterations in Respiration and aROUSal in Patients With Drug-resistant EpiLepsy (NA)
- SMILE Trial - Imaging Sub-Study
- Optimization of Exhaled Biomarker Collection and Analysis (NA)
- Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study (PHASE4)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Use of Nitrous Oxide for Pain and Anxiety Management During Cervical Cerclage Removal- A Multicenter Randomized Controlled Study (NA)
- Clinical Study of Lung Protective Ventilation Strategies and Tumor Microenvironment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxygen inhalation CI brief — competitive landscape report
- oxygen inhalation updates RSS · CI watch RSS
- University of Zurich portfolio CI